Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Curious Case Of FDA, Zarxio’s Name And The USP Monograph

Executive Summary

U.S. Pharmacopeia says if Sandoz’s biosimilar meets the filgrastim monograph, it should carry the same nonproprietary name as Neupogen. FDA says it’s already determined the monograph does not apply, shedding some light on its approach to a temporary name for the first biosimilar.

You may also be interested in...



US FDA, USP Cooperate On Small Molecule Drug Monograph Updates To Speed ANDAs

Generic applicants can request monograph changes while FDA assessment is ongoing.

FDA Claims Sole Authority Over Naming Of US-Licensed Biologics

Deferring to nonproprietary names established by US Pharmacopeia without exercising independent judgment ‘would be untenable,’ FDA says in citizen petition response to industry; agency offers statutory defense of decision to require distinguishable suffixes for all novel biologics and biosimilars.

FDA Claims Sole Authority Over Naming Of US-Licensed Biologics

Deferring to nonproprietary names established by US Pharmacopeia without exercising independent judgment ‘would be untenable,’ FDA says in citizen petition response to industry; agency offers statutory defense of decision to require distinguishable suffixes for all novel biologics and biosimilars.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel